NEOP Neoprobe Collaborators Receive Clearance to Begin Clinical Evaluation of
Lymphatic Agent
DUBLIN, Ohio--(BW HealthWire)--March 7, 2001--Neoprobe Corporation (OTCBB:NEOP - news) today announced that
researchers at the University of California, San Diego (UCSD) Cancer Center have received clearance from the United States Food and Drug Administration to
begin investigational clinical evaluation of a radiolabeled agent designed to assist in the more accurate surgical management and diagnosis of breast cancer patients.
Patient enrollment in the randomized clinical study will begin shortly. Dr. Anne Wallace, assistant professor of surgery and director of the Breast Care Unit at UCSD
Cancer Center, is the principal physician investigator evaluating the agent in breast cancer patients. Dr. Wallace's Phase I clinical study is being funded with a grant
from the Susan G. Komen Breast Cancer Foundation. The clinical study will evaluate the agent's ability, when used with Neoprobe's hand-held gamma radiation
detection instruments, to accurately identify tumor draining lymph nodes.
Neoprobe has completed an option agreement with the Regents of the University of California to exclusively license the proprietary UCSD agent for diagnostic use.
The agent, to which a radioactive isotope is attached, has shown considerable ability in preclinical studies to accurately identify lymphatic tissue. The accurate
identification of the presence or absence of cancer in lymph nodes is of tremendous importance in determining the prognosis and management of breast cancer
patients.
Statements in this news release which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future
financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words ``believe,''
``expect,'' ``anticipate,'' ``estimate,'' ``project,'' and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are
cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many
factors including, but not limited to, the Company's limited revenues, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited
product line and exclusive distributor, uncertainty of market acceptance, competition, limited marketing and manufacturing experience, and other risks detailed in the
Company's most recent Annual Report on Form 10-K and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.
Contact:
CONTACTS: Neoprobe Corporation
David Bupp or Brent L. Larson, 614/793-7500
info@neoprobe.com
www.neoprobe.com |
